Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection

On December 22, 2021, the United States Food and Drug Administration approved the first main protease inhibitor, i.e., oral antiviral nirmatrelvir (PF-07321332)/ritonavir (Paxlovid), for the treatment of early severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Nirmatrelvir inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wujun, Liang, Bing, Wu, Xiaolin, Li, Ling, Wang, Chao, Xing, Dongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Xi'an Jiaotong University 2023
Materias:
Review Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628234/
https://www.ncbi.nlm.nih.gov/pubmed/36345404
http://dx.doi.org/10.1016/j.jpha.2022.10.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628234/
https://www.ncbi.nlm.nih.gov/pubmed/36345404
http://dx.doi.org/10.1016/j.jpha.2022.10.005

Ejemplares similares